

6 References

1. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. *Leukemia*. 2009;23(1):3-9.
2. Hameed A, Brady JJ, Dowling P, Clynes M, O'Gorman P. Bone disease in multiple myeloma: pathophysiology and management. *Cancer Growth Metastasis*. 2014;7:33-42.
3. Bianchi G, Anderson KC. Understanding biology to tackle the disease: multiple myeloma from bench to bedside, and back. *CA Cancer J Clin*. 2014;64(6):422-444.
4. SEER Cancer Stat Facts: Myeloma. National Cancer Institute. Bethesda, MD, <https://seer.cancer.gov/statfacts/html/mulmy.html>.
5. Dhakal B, Einsele H, Potluri R, et al. P899: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed/refractory multiple myeloma from the Optum database. *HemaSphere*. 2022;6:790-791.
6. Dhakal B, Einsele H, Potluri R, et al. P-240: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the SEER-Medicare database. *Clin Lymphoma Myeloma Leuk*. 2022;22:S167.
7. Ravi G, Bal S, Joiner L, et al. Subsequent therapy and outcomes in patients with newly diagnosed multiple myeloma experiencing disease progression after quadruplet combinations. *Br J Haematol*. 2024.
8. Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. *Br J Haematol*. 2016;175(2):252-264.
9. Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis). *Leukemia*. 2024;38(12):2554-2560.
10. Costa LJ, Cornell RF, Callander NS, et al. Efficacy of treatments for patients with triple-class refractory (TCR) multiple myeloma (MM): benchmark for new agents utilizing real-world data (RWD). *Blood*. 2021;138:3786.
11. Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. *Lancet*. 2021;398(10297):314-324.
12. Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. *J Clin Oncol*. 2023;41(6):1265-1274.
13. San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. *N Engl J Med*. 2023;389(4):335-347.

CARVYKTI® (ciltacabtagene autoleucel) US Prix Galien submission. [July 11, 2025]

14. Mateos M-V, San-Miguel J, Dhakal B, et al. Overall survival with ciltacabtagene autoleucel versus standard of care in lenalidomide-refractory multiple myeloma: Phase 3 CARTITUDE-4 study update. *Presented at the 21st International Myeloma Society (IMS) Annual Meeting; September 25–28, 2024; Rio de Janeiro, Brazil.*
15. Jagannath S, Martin TG, Lin Y, et al. Long-term (≥ 5 -year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 Patients with relapsed/refractory multiple myeloma. *J Clin Oncol.* 2025;JCO2500760.
16. Kolata G. From No Hope to a Potential Cure for a Deadly Blood Cancer, Study Shows. *The New York Times.* June 5, 2025, 2025;Section A: 18.
17. Richardson P, Anderson K. Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. *J Clin Oncol.* 2004;22(16):3212-3214.
18. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) version 3.2023. <https://www.nccn.org/guidelines/guidelines-detail?category=patients&id=24>. Published 2023. Updated December 8, 2022. Accessed.
19. US Food and Drug Administration. Lenalidomide (Revlimid). <https://www.fda.gov/drugs/resources-information-approved-drugs/lenalidomide-revlimid>. Published 2017. Accessed April 10, 2017, 2023.
20. Food and Drug Administration. Application number: 021430 approval letter. In:2006.
21. National Cancer Institute. Pomalidomide plus low-dose dexamethasone improves survival for patients with multiple myeloma. <https://www.cancer.gov/types/myeloma/research/pomalidomide-dexamethasone>. Published 2013. Accessed April 10, 2023, 2023.
22. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. *Oncologist.* 2003;8(6):508-513.
23. Herndon TM, Deisseroth A, Kaminskis E, et al. U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. *Clin Cancer Res.* 2013;19(17):4559-4563.
24. Takeda Pharmaceutical Company Limited. U.S. FDA approves Takeda's NINLARO® (ixazomib), the first and only oral proteasome inhibitor to treat multiple myeloma. <https://www.takeda.com/newsroom/newsreleases/2015/u.s.-fda-approves-takedas-ninlaro-ixazomib-the-first-and-only-oral-proteasome-inhibitor-to-treat-multiple-myeloma>. Published 2015. Accessed April 10, 2023.
25. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. *J Immunol.* 2011;186(3):1840-1848.
26. Rodriguez-Otero P, Paiva B, Engelhardt M, Prosper F, San Miguel JF. Is immunotherapy here to stay in multiple myeloma? *Haematologica.* 2017;102(3):423-432.

CARVYKTI® (ciltacabtagene autoleucel) US Prix Galien submission. [July 11, 2025]

27. Bhatnagar V, Gormley NJ, Luo L, et al. FDA approval summary: daratumumab for treatment of multiple myeloma after one prior therapy. *Oncologist*. 2017;22(11):1347-1353.
28. Dhillon S. Isatuximab: first approval. *Drugs*. 2020;80(9):905-912.
29. van de Donk N. Sequencing multiple myeloma therapies with and after antibody therapies. *Hematology Am Soc Hematol Educ Program*. 2020;2020(1):248-258.
30. de Arriba de la Fuente F, Montes Gaisan C, de la Rubia Comos J. How to manage patients with lenalidomide-refractory multiple myeloma. *Cancers (Basel)*. 2022;15(1):155.
31. Meeting of the Oncologic Drugs Advisory Committee - Janssen Presentations (CARVYKTI). In:2024.
32. US Food and Drug Administration. FDA approves new treatment for refractory multiple myeloma. <https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-refractory-multiple-myeloma>. Published 2019. Accessed April 10, 2023, 2023.
33. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. *N Engl J Med*. 2019;381(8):727-738.
34. Munshi NC, Anderson LD, Jr., Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. *N Engl J Med*. 2021;384(8):705-716.
35. Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. *Lancet Oncol*. 2020;21(2):207-221.
36. Lonial S, Lee HC, Badros A, et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. *Cancer*. 2021;127(22):4198-4212.
37. Rodriguez-Otero P, van de Donk N, Pillarisetti K, et al. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. *Blood Cancer J*. 2024;14(1):24.
38. Xu J, Chen LJ, Yang SS, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. *Proc Natl Acad Sci U S A*. 2019;116(19):9543-9551.
39. Zhao WH, Liu J, Wang BY, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. *J Hematol Oncol*. 2018;11(1):141.
40. Zhao WH, Wang BY, Chen LJ, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). *J Hematol Oncol*. 2022;15(1):86.

CARVYKTI® (ciltacabtagene autoleucel) US Prix Galien submission. [July 11, 2025]

41. Mi JQ, Zhao WH, Chen LJ, et al. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment of LCAR-B38M CAR-T – at least 5-year follow-up in LEGEND-2. *J Clin Oncol.* 2023;41 (suppl 16):Abstract 8010.
42. Lin Y, Martin TG, Usmani SZ, et al. CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. *J Clin Oncol.* 2023;41 (suppl 16):Abstract 8009.
43. Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. *Front Immunol.* 2018;9:1821.
44. Tai YT, Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. *Immunotherapy.* 2015;7(11):1187-1199.
45. Claudio JO, Masih-Khan E, Tang H, et al. A molecular compendium of genes expressed in multiple myeloma. *Blood.* 2002;100(6):2175-2186.
46. Tai YT, Mayes PA, Acharya C, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. *Blood.* 2014;123(20):3128-3138.
47. Bouchkouj N, Kasamon YL, de Claro RA, et al. FDA approval summary: axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. *Clin Cancer Res.* 2019;25(6):1702-1708.
48. Kymriah USPI. KYMRIAH® (tisagenlecleucel) prescribing information. https://www.novartis.com/us-en/sites/novartis_us/files/kymriah.pdf. Accessed May 18, 2023, 2023.
49. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. *Annu Rev Med.* 2014;65:333-347.
50. Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. *Am J Hematol.* 2019;94(S1):S3-S9.
51. Srivastava S, Riddell SR. Engineering CAR-T cells: design concepts. *Trends Immunol.* 2015;36(8):494-502.
52. Weinkove R, George P, Dasyam N, McLellan AD. Selecting costimulatory domains for chimeric antigen receptors: functional and clinical considerations. *Clin Transl Immunology.* 2019;8(5):e1049.
53. Blaesche F, Stenger D, Kaeuferle T, et al. Induction of a central memory and stem cell memory phenotype in functionally active CD4(+) and CD8(+) CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19(+) acute lymphoblastic leukemia. *Cancer Immunol Immunother.* 2018;67(7):1053-1066.
54. Zudaire E, Madduri D, Usmani SZ, et al. Translational analysis from CARTITUDE-1, an ongoing phase 1b/2 study of JNJ-4528 BCMA-targeted CAR-T cell therapy in relapsed

CARVYKTI® (ciltacabtagene autoleucel) US Prix Galien submission. [July 11, 2025]

- and/or refractory multiple myeloma (R/R MM), indicates preferential expansion of CD8+ T cell central memory cell subset. *Blood*. 2019;134(Supplement_1):928-928.
55. Madduri D, Usmani SZ, Jagannath S, et al. Results from CARTITUDE-1: a phase 1b/2 study of JNJ-4528, a CAR-T cell therapy directed against B-cell maturation antigen (BCMA), in patients with relapsed and/or refractory multiple myeloma (R/R MM). *Blood*. 2019;134(Supplement_1):577.
 56. de Larrea CF, Harrison S, Martinez-Lopez J, et al. OA-45 Pharmacokinetic and correlative analysis of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma in the CARTITUDE-4 trial. *Clin Lymphoma Myeloma Leuk*. 2023;23:S28.
 57. Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. *JAMA Oncol*. 2017;3(1):28-35.
 58. Martin T, Mikhael J, Hajek R, et al. Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. *Blood Adv*. 2022;6(15):4506-4515.
 59. Jakubowiak A, Usmani SZ, Berdeja JG, et al. Efficacy and safety of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 subgroup analysis. *Blood*. 2021;138(Supplement 1):3938.
 60. CARVYKTI. In. Horsham, PA: Janssen Biotech; April 2024.
 61. Mateos M-V, San-Miguel J, Dhakal B, et al. Overall survival with ciltacabtagene autoleucel versus standard of care in lenalidomide-refractory multiple myeloma: phase 3 CARTITUDE-4 study update. *Presented at the 21st International Myeloma Society (IMS) Annual Meeting; September 25–28, 2024; Rio de Janeiro, Brazil*.
 62. Sidana S, Martinez-Lopez J, Khan AM, et al. Ciltacabtagene autoleucel (cilta-cel) vs standard of care (SOC) in patients (pts) with relapsed/refractory multiple myeloma (MM): CARTITUDE-4 survival subgroup analyses. *J Clin Oncol*. 2025;43(16_suppl):7539-7539.
 63. Dhakal B, Yong K, Harrison S, et al. First phase 3 results from CARTITUDE-4: cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. *J Clin Oncol*. 2023: Accepted. Abstract 106.
 64. Mina R, Mylin AK, Yokoyama H, et al. Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. *Lancet Haematol*. 2025;12(1):e45-e56.
 65. Martin T, Lin Y, Agha M, et al. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study. *Lancet Haematol*. 2022;9(12):e897-e905.
 66. Cohen AD, Hari P, Htut M, et al. Patient perceptions regarding ciltacabtagene autoleucel treatment: qualitative evidence from interviews with patients with relapsed/refractory

CARVYKTI® (ciltacabtagene autoleucel) US Prix Galien submission. [July 11, 2025]

multiple myeloma in the CARTITUDE-1 study. *Clin Lymphoma Myeloma Leuk*. 2023;23(1):68-77.

67. Legend Biotech USA Inc. U.S. Food and Drug Administration grants breakthrough therapy designation for JNJ-68284528, an investigational BCMA CAR-T cell therapy. https://legendbiotech.com/wp-content/uploads/2022/08/JNJ4528_Breakthrough_Therapy_Designation_Release.pdf. Published 2019. Accessed March 21, 2023, 2023.
68. The Janssen Pharmaceutical Companies of Johnson & Johnson. Janssen announces CAR-T therapy ciltacabtagene autoleucel (cilta-cel) accepted for accelerated assessment in Europe for the treatment of patients with heavily pretreated multiple myeloma. <https://www.businesswire.com/news/home/20210201005446/en/Janssen-Announces-CAR-T-Therapy-Ciltacabtagene-Autoleucel-Cilta-cel-Accepted-for-Accelerated-Assessment-in-Europe-for-the-Treatment-of-Patients-with-Heavily-Pretreated-Multiple-Myeloma>. Published 2021. Accessed March 21, 2023, 2023.
69. Kochenderfer JN, Feldman SA, Zhao Y, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. *J Immunother*. 2009;32(7):689-702.
70. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. *N Engl J Med*. 2011;365(8):725-733.
71. Teoh J, Brown LF. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19(+) hematologic indications. *Cytotherapy*. 2022;24(9):962-973.
72. Gilead Sciences Inc. TECARTUS (brexucabtagene autoleucel) prescribing information. <https://www.gilead.com/-/media/files/pdfs/medicines/oncology/tecartus/tecartus-pi.pdf>. Published 2021. Accessed April 10, 2023, 2023.
73. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR t-cell therapy bb2121 in relapsed or refractory multiple myeloma. *N Engl J Med*. 2019;380(18):1726-1737.
74. Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. *Leukemia*. 2022;36(5):1371-1376.
75. Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. *Leukemia*. 2019;33(9):2266-2275.
76. Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. *BMC Cancer*. 2020;20(1):1087.
77. Popat R, Oriol A, Cavo M, et al. Ciltacabtagene autoleucel vs standard of care in patients with lenalidomide-refractory multiple myeloma after 1–3 lines of therapy: Minimal residual disease negativity in the Phase 3 CARTITUDE-4 trial. *Presented at the 66th American Society of Hematology (ASH) Annual Meeting; December 7–10, 2024; San Diego, CA, USA*.

CARVYKTI® (ciltacabtagene autoleucel) US Prix Galien submission. [July 11, 2025]

78. Sidiqi MH, Corradini P, Purtill D, et al. Efficacy and safety in patients with lenalidomide-refractory multiple myeloma after 1-3 prior lines who received a single infusion of ciltacabtagene autoleucel as study treatment in the phase 3 CARTITUDE-4 trial. *Blood*. 2023;142(Supplement 1):4866-4866.
79. Manier S, San-Miguel J, Dhakal B, et al. OA-47 Additional analysis of CARTITUDE-4: Cilta-cel vs standard of care (PVd or DPd) in lenalidomide-refractory patients with multiple myeloma and 1–3 prior lines of therapy. *Clin Lymphoma Myeloma Leuk*. 2023;23:S29-S30.
80. Arnulf B, Kerre T, Agha ME, et al. Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D. *J Clin Oncol*. 2024;42(16_suppl):7505-7505.
81. Bazarbachi AH, Al Hamed R, Malard F, Bazarbachi A, Harousseau JL, Mohty M. Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. *Blood Cancer J*. 2022;12(3):47.
82. Comment from ANNE STOVELL. US General Services Administration. <https://www.regulations.gov/comment/FDA-2024-N-0018-0013>. Published 2024. Accessed May 1, 2024, 2024.
83. Voorhees PM, Martin TG, Lin Y, et al. Long-term (≥ 5 year) remission and survival after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 patients (pts) with relapsed/refractory multiple myeloma (RRMM). *J Clin Oncol*. 2025;43(16_suppl):7507-7507.
84. Jagannath S, Martin TG, Lin Y, et al. Long-term (≥ 5 year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed/refractory multiple myeloma. *European Hematology Association*. 2025;S192.
85. Martin T. Thomas Martin, MD, on moving forward with cilta-cel treatment in multiple myeloma. <https://www.cancernetwork.com/view/thomas-martin-md-on-moving-forward-with-cilta-cel-treatment-in-multiple-myeloma>. Published 2022. Accessed April 10, 2023, 2023.
86. Legend Biotech USA Inc. Longer-term data from CARTITUDE program continue to show deep and durable responses with ciltacabtagene autoleucel across lines of therapy in patients with multiple myeloma. <https://investors.legendbiotech.com/news-releases/news-release-details/longer-term-data-cartitude-program-continue-show-deep-and>. Published 2022. Accessed April 10, 2023, 2023.
87. Legend Biotech USA Inc. CARVYKTI™ (ciltacabtagene autoleucel), BCMA-directed CAR-T therapy, receives U.S. FDA approval for the treatment of adult patients with relapsed or refractory multiple myeloma. <https://investors.legendbiotech.com/news-releases/news-release-details/carvykiti-ciltacabtagene-autoleucel-bcma-directed-car-t-therapy>. Published 2022. Accessed April 10, 2023, 2023.
88. Usmani SZ, Sidana S. Public comment for FDA Oncologic Drugs Advisory Committee Meeting. March 15, 2024.